395 related articles for article (PubMed ID: 32021502)
1. Myositis Specific Autoantibodies: A Clinical Perspective.
Alenzi FM
Open Access Rheumatol; 2020; 12():9-14. PubMed ID: 32021502
[TBL] [Abstract][Full Text] [Related]
2. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
[TBL] [Abstract][Full Text] [Related]
3. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
[TBL] [Abstract][Full Text] [Related]
4. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
Satoh M; Tanaka S; Ceribelli A; Calise SJ; Chan EK
Clin Rev Allergy Immunol; 2017 Feb; 52(1):1-19. PubMed ID: 26424665
[TBL] [Abstract][Full Text] [Related]
5. Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.
He L
Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1064-1068. PubMed ID: 34719424
[TBL] [Abstract][Full Text] [Related]
6. Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China.
Zhao Y; Su H; Yin X; Hou H; Wang Y; Xu Y; Li X; Zhang N; Sun W; Wei W
Med Clin (Barc); 2023 Jan; 160(1):10-16. PubMed ID: 35842306
[TBL] [Abstract][Full Text] [Related]
7. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
8. Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population.
Manwatkar A; Padiyar S; Nair A; Jha A; Kumar S; Yadav B; Prakash JAJ; Das JK; Mathew J
Clin Rheumatol; 2023 Dec; 42(12):3289-3297. PubMed ID: 37801141
[TBL] [Abstract][Full Text] [Related]
9. Anti-Mi-2 and Anti-TIF1-γ Double-Positive Juvenile Dermatomyositis Treated under Diagnosis of Chronic Eczema: A Case Report.
Yoshida S; Matsumoto H; Fujita Y; Yokose K; Temmoku J; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Yaguchi T; Aita T; Kusano M; Yamamoto T; Watanabe H; Migita K
Tohoku J Exp Med; 2022 Apr; 256(4):303-308. PubMed ID: 35296571
[TBL] [Abstract][Full Text] [Related]
10. [Myositis-specific autoantibodies].
Fujimoto M
Brain Nerve; 2013 Apr; 65(4):449-60. PubMed ID: 23568993
[TBL] [Abstract][Full Text] [Related]
11. Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis.
Gono T; Kuwana M
Expert Rev Clin Immunol; 2020 Jan; 16(1):79-89. PubMed ID: 31779485
[No Abstract] [Full Text] [Related]
12. Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.
Muro Y; Sugiura K; Akiyama M
Clin Rev Allergy Immunol; 2016 Dec; 51(3):293-302. PubMed ID: 26100618
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
[TBL] [Abstract][Full Text] [Related]
14. Dermatomyositis: Clinical features and pathogenesis.
DeWane ME; Waldman R; Lu J
J Am Acad Dermatol; 2020 Feb; 82(2):267-281. PubMed ID: 31279808
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional intermediary factor 1 (TIF1) and anti-TIF1γ antibody-positive dermatomyositis.
Kotobuki Y; Tonomura K; Fujimoto M
Immunol Med; 2021 Mar; 44(1):23-29. PubMed ID: 32649853
[TBL] [Abstract][Full Text] [Related]
16. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China.
Wen L; Chen X; Cheng Q; Nie L; Xu J; Yan T; Zhang X; Yang H; Sun W; Liu L; Xue J; Du Y
Clin Rheumatol; 2022 Nov; 41(11):3419-3427. PubMed ID: 35859245
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
19. Anti-PL-7, anti-Ro/SSA, anti-Mi-2, and anti-TIF1-γ correlate with specific patterns of histopathologic features in dermatomyositis: An analysis of 39 skin biopsy specimens from 25 patients.
Bennett R; Bradley K; Stevanovic M; McFadden JR; Chaudhari AS; Ramos-Rodriguez AJ; Yan S; Momtahen S; LeBlanc RE; Cloutier JM; Salem I; Grand DG; Hodson EL; Sriharan A
J Cutan Pathol; 2024 Apr; 51(4):317-326. PubMed ID: 38158735
[TBL] [Abstract][Full Text] [Related]
20. Trichoscopic, oral, and periungual fold findings as activity and damage markers in dermatomyositis patients and their correlation with myositis antibodies.
Salgueiro C; Poblete MJ; Robles-Silva C; Abarzúa Á; Vera-Kellet C
Arch Dermatol Res; 2023 Aug; 315(6):1603-1613. PubMed ID: 36757439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]